がん治療学部

1. Kota Washimi, Yukihiko Hiroshima, Shinya Sato, Makoto Ueno, Satoshi Kobayashi, Naoto Yamamoto, Chie Hasegawa, Emi Yoshioka, Kyoko Ono, Yoichiro Okubo, Tomoyuki Yokose, Yohei Miyagi. Evaluation of pancreatic cancer specimens for comprehensive genomic profiling (CGP). Pathology International. in press. IF=2.2
2. Oshima T, Hashimoto I, Hiroshima Y, Kimura Y, Tanabe M, Onuma S, Morita J, Nagasawa S, Kanematsu K, Aoyama T, Yamada T, Ogata T, Rino Y, Saito A, Miyagi Y. Clinical Significance of Tryptophanyl-tRNA Synthetase 1 Gene Expression in Patients With Locally Advanced Gastric Cancer. Anticancer Res. 2024 Feb;44(2):673-678. doi: 10.21873/anticanres.16857.PMID: 38307580. IF=2.0
3. Toda S, Iwasaki H, Okubo Y, Hayashi H, Kadoya M, Takahashi H, Yokose T, Hiroshima Y, Masudo K.The frequency of mutations in advanced thyroid cancer in Japan: a single-center study. Endocr J. 2024 Jan 29;71(1):31-37. doi: 10.1507/endocrj.EJ23-0342. Epub 2023 Dec 1.PMID: 38044137. IF=2.9
4. Oshima T, Hashimoto I, Hiroshima Y, Kimura Y, Tanabe M, Onuma S, Nagasawa S, Kanematsu K, Aoyama T, Yamada T, Ogata T, Rino Y, Saito A, Miyagi Y. Asialoglycoprotein Receptor 2 Expression in Patients With Locally Advanced Gastric Cancer After Curative Resection. Anticancer Res. 2024 Jan;44(1):397-402. doi: 10.21873/anticanres.16824.PMID: 38159992. IF=2.0
5. Oshima T, Hashimoto I, Hiroshima Y, Kimura Y, Tanabe M, Onuma S, Morita J, Nagasawa S, Kanematsu K, Aoyama T, Yamada T, Ogata T, Rino Y, Saito A, Miyagi Y.Clinical Significance of Pregnancy Zone Protein Expression in Patients With Locally Advanced Gastric Cancer After Curative Resection. Anticancer Res. 2024 Jan;44(1):369-374. doi: 10.21873/anticanres.16820.PMID: 38159976. IF=2.0
6. Oshima T, Hashimoto I, Hiroshima Y, Kimura Y, Tanabe M, Onuma S, Nagasawa S, Kanematsu K, Aoyama T, Yamada T, Ogata T, Rino Y, Saito A, Miyagi Y.Clinical Significance of Chitinase-3-like Protein 1 Gene Expression in Patients With Locally Advanced Gastric Cancer. Anticancer Res. 2024 Jan;44(1):307-312. doi: 10.21873/anticanres.16813. IF=2.0
7. Hiroaki Goto, Takashi Ohtsu, Mieko Ito, Maiko Sagisaka, Takuya Naruto, Jun-Ichi Nagai, Norihiko Kitagawa, Mio Tanaka, Masakatsu Yanagimachi, Yukihiko Hiroshima, Yohei Miyagi. A short-term three dimensional culture-based drug sensitivity test is feasible for malignant bone tumors. Hum Cell. 2023 Nov;36(6):2152-2161. doi: 10.1007/s13577-023-00982-8. PMID: 37707773. IF=4.3
8. Yuta Ueno, Emiko Yoshida, Shuko Nojiri, Tomoyasu Kato, Takashi Ohtsu, Toshiyuki Takeshita, Shunji Suzuki, Hiroshi Yoshida, Ken Kato, Masayoshi Itoh, Tsuguto Notomi, Kengo Usui, Takashi Sozu, Yasuhisa Terao, Hideya Kawaji and Hisamori Kato.Use of clinical variables for preoperative prediction of lymph node metastasis in endometrial cancer. Jpn J Clin Oncol. 2024 Jan 7;54(1):38-46. doi: 10.1093/jjco/hyad135. PMID: 37815156. IF=2.4
9. Sato S, Hiruma T, Koizumi M, Yoshihara M, Nakamura Y, Tadokoro H, Motomatsu S, Yamanaka T, Washimi K, Okubo Y, Yoshioka E, Kasajima R, Yamashita T, Kishida T, Yokose T, Miyagi Y. Bone marrow adipocytes induce cancer-associated fibroblasts and immune evasion, enhancing invasion and drug resistance. Cancer Sci 114(6):2674-2688, 2023. (Published 2023 Jun)　IF=5.7
10. Koizume S, Kanayama T, Kimura Y, Hirano H, Takahashi T, Ota Y, Miyazaki K, Yoshihara M, Nakamura Y, Yokose T, Kato H, Takenaka K, Sato S, Tadokoro H, Miyagi E, Miyagi Y. Cancer cell-derived CD69 induced under lipid and oxygen starvation promotes ovarian cancer progression via fibronectin. Cancer Sci 114(6):2485-2498, 2023. (Published 2023 Jun)　IF=5.7

1. Hasegawa C, Washimi K, Hiroshima Y, Kasajima R,Kikuchi K, Notomi T, Kato H, Hiruma T, Sato S, OkuboY, Yoshioka E, Ono K, Miyagi Y, Yokose T. Differentialdiagnosis of uterine adenosarcoma: identification ofJAZF1-BCORL1 rearrangement by comprehensivecancer genomic profiling. Diagn Pathol. 2023 Jan13;18(1): 5. doi: 10.1186/s13000-022-01279-4.PMID:36639698.
2. Suematsu H, Sakamaki K, Oue N, Hiroshima Y,Kimura Y, Onuma S, Hashimoto I, Nagasawa S,Aoyama T, Yamada T, Tamagawa H, Ogata T, RinoY, Masuda M, Yasui W, Miyagi Y, Oshima T. ClinicalSignificance of SEC11A Expression in Patients WithLocally Advanced Gastric Cancer. Anticancer Res. 2022Dec; 42(12): 5885-5890. doi: 10.21873/anticanres.16097.PMID: 36456166.
3. Hashimoto I, Kimura Y, Oue N, Hiroshima Y,Aoyama T, Rino Y, Yokose T, Yasui W, Miyagi Y,Oshima T. Identification of a Biomarker Combinationfor Survival Stratification in pStage Ⅱ / Ⅲ GastricCancer after Curative Resection. Cancers (Basel). 2022Sep 12; 14(18): 4427. doi: 10.3390/cancers14184427.PMID: 36139587.
4. Suematsu H, Hashimoto I, Hiroshima Y, WatanabeH, Kano K, Takahashi K, Aoyama T, Yamada T,Tamagawa H, Ogata T, Yukawa N, Rino Y, MasudaM, Miyagi Y, Oshima T. Clinical Significance of EREGGene Expression in Gastric Cancer Tissue AfterCurative Surgery. Anticancer Res. 2022 Aug;42(8):3873-3878. doi: 10.21873/anticanres.15880. PMID: 35896250.

2021年

1. Minegishi Y, Hiroshima Y, Yazawa K, Sato S, Yabushita Y, Homma Y, Matsuyama R, Kato I, Goshima Y, Endo I. CRMP4 Up-regulates M2 Macrophages and Myeloid-derived Suppressor Cells to Promote Pancreatic Cancer in Mice. Anticancer Res. 2022 Feb;42(2):791-799. doi: 10.21873/anticanres.15537. PMID: 35093877. IF=2.48
2. Mizuno T, Yoshida T, Sunami K, Koyama T, Okita N, Kubo T, Sudo K, Shimoi T, Ueno H, Saito E, Katanoda K, Shibata T, Yonemori K, Okusaka T, Boku N, Ohe Y, Hiroshima Y, Ueno M, Kuboki Y, Doi T, Nakamura K, Kohno T, Yatabe Y, Yamamoto N. Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients. Jpn J Clin Oncol. 2021 Dec 1;51(12):1757-1760. doi: 10.1093/jjco/hyab159. PMID: 34622931. IF=3.02
3. Nagasawa S, Tsuchida K, Shiozawa M, Hiroshima Y, Kimura Y, Hashimoto I, Watanabe H, Kano K, Numata M, Aoyama T, Sato S, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Morinaga S, Yukawa N, Rino Y, Masuda M, Saeki H, Miyagi Y, Oshima T. Clinical Significance of Chemokine Receptor CXCR4 and CCR7 mRNA Expression in Patients With Colorectal Cancer. Anticancer Res. 2021 Sep;41(9):4489-4495. doi: 10.21873/anticanres.15259. PMID: 34475074. IF=2.48
4. Segami K, Aoyama T, Hiroshima Y, Komori K, Hashimoto I, Watanabe H, Kano K, Nagasawa S, Nakazono M, Maezawa Y, Fujikawa H, Numata M, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Shiozawa M, Yukawa N, Morinaga S, Rino Y, Masuda M, Miyagi Y, Saeki H, Oshima T. Clinical Significance of TAP1 and DLL4 Expression in Patients With Locally Advanced Gastric Cancer. In Vivo. 2021 Sep-Oct;35(5):2771-2777. doi: 10.21873/invivo.12562. PMID: 34410967 Free PMC article. IF=2.16
5. Hashiguchi MH, Sato T, Watanabe R, Kagyo J, Matsuzaki T, Domoto H, Kato T, Nakahara Y, Yokose T, Hiroshima Y, Shiomi T. A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib. Thorac Cancer. 2021 Sep;12(18):2504-2507. doi: 10.1111/1759-7714.14093. Epub 2021 Jul 28. PMID: 34319660 Free PMC article. IF=3.5
6. Hatori S, Sakamaki K, Yokohori T, Kimura Y, Hiroshima Y, Hashimoto I, Komori K, Watanabe H, Kano K, Fujikawa H, Aoyama T, Numata M, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Shizawa M, Yukawa N, Morinaga S, Rino Y, Masuda M, Saeki H, Miyagi Y, Oshima T. Clinical Significance of PLA2G2A Expression in Gastric Cancer Patients who Receive Gastrectomy and Adjuvant S-1. Anticancer Res. 2021 Jul;41(7):3583-3588. doi: 10.21873/anticanres.15146. PMID: 34230154. IF=2.48
7. Kobayashi N, Takeda Y, Okubo N, Suzuki A, Tokuhisa M, Hiroshima Y, Ichikawa Y. Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma. Cancer Sci. 2021 May;112(5):1936-1942. doi: 10.1111/cas.14811. Epub 2021 Mar 12. PMID: 33453146 Free PMC article. Clinical Trial. IF=6.72
8. Nukada S, Okubo Y, Shiozawa M, Yoshioka E, Suzuki M, Washimi K, Kawachi K, Sato S, Hiroshima Y, Rino Y, Yokose T, Masuda M. Signet-ring Cell Carcinoma Component as an Indicator of Anaplastic Lymphoma Kinase Mutations in Colorectal Cancer. J Anus Rectum Colon. 2021 Apr 28;5(2):167-172. doi: 10.23922/jarc.2020-068. eCollection 2021. PMID: 33937557 Free PMC article. IF=NA
9. Watanabe T, Shiozawa M, Kimura Y, Hiroshima Y, Hashimoto I, Komori K, Watanabe H, Kano K, Fujikawa H, Aoyama T, Numata M, Yamada T, Tamagawa H, Ogata T, Yukawa N, Morinaga S, Rino Y, Masuda M, Miyagi Y, Oshima T. Clinical Significance of Stanniocalcin2 mRNA Expression in Patients With Colorectal Cancer. Anticancer Res. 2021 Apr;41(4):2117-2122. doi: 10.21873/anticanres.14983. PMID: 33813422. IF=2.48

2020年

1. Kobayashi N, Takeda Y, Okubo N, Suzuki A, Tokuhisa M, Hiroshima Y, Ichikawa Y. Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma. Cancer Sci. 2021 Jan 16. IF=4.966
2. Matsuki H, Hiroshima Y, Miyake K, Murakami T, Homma Y, Matsuyama R, Morioka D, Kurotaki D, Tamura T, Endo I. Reduction of gender-associated M2-like tumor-associated macrophages in the tumor microenvironment of patients with pancreatic cancer after neoadjuvant chemoradiotherapy. J Hepatobiliary Pancreat Sci. 2021 Feb;28(2):174-182. IF=4.16
3. Murata T, Hozumi C, Hiroshima Y, Shimoya K, Hongo A, Inubushi S, Tanino H, Hoffman RM. Co-implantation of Tumor and Extensive Surrounding Tissue Improved the Establishment Rate of Surgical Specimens of Human-Patient Cancer in Nude Mice: Toward the Goal of Universal Individualized Cancer Therapy. In Vivo. 2020 Nov-Dec;34(6):3241-3245. IF=1.609
4. Nagashima T, Oshima T, Hiroshima Y, Yokose T, Woo T, Rino Y, Masuda M, Miyagi Y, Ito H, Nakayama H. Clinical Significance of Tumour CD44v and MIST1 Expression in Patients With Non-small-cell Lung Cancer. Anticancer Res. 2020 Nov;40(11):6407-6416. IF=1.99
5. Hashimoto I, Oue N, Kimura Y, Hiroshima Y, Hara K, Maezawa Y, Kano K, Fujikawa H, Aoyama T, Numata M, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Shiozawa M, Morinaga S, Rino Y, Yasui W, Masuda M, Miyagi Y, Oshima T. Clinical Significance of Glioma-associated Oncogene 1 Expression in Patients With Locally Advanced Gastric Cancer Administered Adjuvant Chemotherapy With S-1 After Curative Surgery. Anticancer Res. 2020 Oct;40(10):5815-5821. IF=1.99
6. Oshima T, Yoshikawa T, Miyagi Y, Morita S, Yamamoto M, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Yokose T, Hiroshima Y, Aoyama T, Hayashi T, Ogata T, Cho H, Rino Y, Masuda M, Tsuburaya A, Sakamoto J. Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial. Oncotarget. 2020 Jul 28;11(30):2906-2918. IF=3.93
7. Igarashi K, Kawaguchi K, Murakami T, Miyake K, Kiyuna T, Miyake M, Hiroshima Y, Higuchi T, Oshiro H, Nelson SD, Dry SM, Li Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Singh SR, Tsuchiya H, Hoffman RM. Patient-derived orthotopic xenograft models of sarcoma. Cancer Lett. 2020 Jan 28;469:332-339. IF=6.508
8. Yazawa K, Nakamura F, Masukawa D, Sato S, Hiroshima Y, Yabushita Y, Mori R, Matsuyama R, Kato I, Taniguchi H, Goshima Y, Endo I. Low Incidence of High-Grade Pancreatic Intraepithelial Neoplasia Lesions in a Crmp4 Gene-Deficient Mouse Model of Pancreatic Cancer. Transl Oncol. 2020 Mar;13(3):100746. IF=3.558
9. Hiroto Onozawa, Haruhiro Saito, Kuniko Sunami, Takashi Kubo, Noboru Yamamoto, Rika Kasajima, Takashi Ohtsu, Yukihiko Hiroshima, Heiwa Kanamori, Tomoyuki Yokose, Yohei Miyagi. Lung adenocarcinoma in a patient with a cis EGFR L858R‐K860I doublet mutation identified using NGS‐based profiling test: Negative diagnosis on initial companion test and successful treatment with Osimertinib. Thoracic Cancer. 2020 Dec;11(12):3599-3604. IF=2.22
10. Kano K, Sakamaki K, Oue N, Kimura Y, Hashimoto I, Hara K, Maezawa Y, Aoyama T, Fujikawa H, Hiroshima Y, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Cho H, Ito H, Shiozawa M, Yukawa N, Yoshikawa T, Morinaga S, Rino Y, Yasui W, Masuda M, Miyagi Y, Oshima T. Impact of the ESM-1 Gene Expression on Outcomes in Stage II/III Gastric Cancer Patients Who Received Adjuvant S-1 Chemotherapy. In Vivo. 2020 Feb;34(1):461-467. IF=1.609
11. Hiroshima Y, Kasajima R, Kimura Y, Komura D, Ishikawa S, Ichikawa Y, Bouvet M, Yamamoto N, Oshima T, Morinaga S, Singh SR, Hoffman RM, Endo I, Miyagi Y. Novel targets identified by integrated cancer-stromal interactome analysis of pancreatic adenocarcinoma. Cancer Lett.2020 Jan 28;469:217-227. IF=6.508